Trial Profile
A Pilot Study Assessing the Feasibility of a Randomized Controlled Trial Investigating Primary Thromboprophylaxis With Rivaroxaban in Patients With Malignancy and Central Venous Catheters
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Jul 2020
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Catheter thrombosis; Venous thromboembolism
- Focus Therapeutic Use
- Acronyms TRIM-Line
- 22 Jul 2020 Status changed from recruiting to completed.
- 09 Aug 2019 Planned End Date changed from 31 Dec 2018 to 1 Apr 2020.
- 09 Aug 2019 Planned primary completion date changed from 31 Oct 2018 to 30 Dec 2019.